文献速递白血病

成人B细胞前体急性淋巴细胞白血病t(1;19)/TCF3-PBX1的预后异质性

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
PubMed 文献 · Br J Haematol · 2021-09-21

本研究分析接受MRD导向方案治疗的青少年和成人t(1;19)(q23;p13)/TCF3-PBX1急性淋巴细胞白血病患者结局,发现其MRD清除率及生存与其他B细胞前体ALL患者相似,但累积复发率显著更高,尤其≥35岁且携带额外细胞遗传学异常者。

要点

  • TCF3-PBX1患者MRD清除率和生存与其他B细胞前体ALL患者相似。
  • TCF3-PBX1患者累积复发率显著更高。
  • ≥35岁伴额外细胞遗传学异常者复发风险尤其突出,或需强化治疗。

核心结论

  • TCF3-PBX1患者总体生存与其它B细胞前体ALL相似,但累积复发率显著更高,尤其在≥35岁伴额外细胞遗传学异常者中。

研究设计与样本

  • 分析纳入儿科启发试验的青少年和成人t(1;19)(q23;p13)急性淋巴细胞白血病患者结局。

主要发现

  • TCF3-PBX1患者MRD清除率与其他B细胞前体ALL患者相似。
  • TCF3-PBX1患者生存与其他B细胞前体ALL患者无差异。
  • TCF3-PBX1患者累积复发率显著更高,尤其≥35岁伴额外细胞遗传学异常者。

临床怎么用

  • 对TCF3-PBX1患者尤其是≥35岁伴额外细胞遗传学异常者,可考虑额外或强化治疗如首次完全缓解期免疫治疗联合或不联合后续造血干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ribera J, Granada I, Morgades M, et al. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br J Haematol. 2021. PMID: 34549416. doi:10.1111/bjh.17844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。